SecBot SecBot

CRVS drug pipeline

$10.60
−0.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.4%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
Time to marketIf the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.

soquelitinib Updated Nov 6

What to watch

The next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.

Bull case
  • Soquelitinib has a novel, differentiated mechanism as a first-in-class oral selective ITK inhibitor with over 100-fold selectivity over related kinases, offering a potential new treatment approach for T-cell lymphomas and immune-inflammatory diseases.
  • Phase 1/1b PTCL data published in Blood showed a 37.5% overall response rate and a median overall survival of 28.1 months in the 200 mg BID cohort, comparing favorably to historical results with current therapies. The FDA granted both Orphan Drug and Fast Track designations.
  • The company has a strong cash runway: $202.9 million as of September 30, 2026, funding operations into Q2 2028, following a $189.4 million financing in January 2026. This eliminates near-term dilution risk.
Bear case
  • Soquelitinib is still in clinical development with no approved products or revenue; the company reported a Q3 2026 net loss of $20.3 million. The Phase 3 PTCL futility analysis in Q1 2027 is a binary risk: if the interim analysis fails, the entire oncology program could be jeopardized.
  • The Phase 1/1b PTCL data (37.5% ORR, n=~32) came from a small, uncontrolled trial. Larger randomized Phase 3 data may not replicate those results against active comparators (belinostat or pralatrexate).
  • The atopic dermatitis market is crowded with approved JAK inhibitors and biologics (Dupixent, Rinvoq, Cibinqo). Soquelitinib's Phase 2 data in Q3 2027 will need to show a clear differentiation to justify further investment.

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Aug 6, 2026soquelitinibFast Track−0.1%+8.7%
Aug 6, 2026soquelitinibOrphan drug designation−0.1%+8.7%
May 7, 2026soquelitinibFast Track+0.7%−11.6%
May 7, 2026soquelitinibOrphan drug designation+0.7%−11.6%